Apple Maps users could start seeing ads in the app as soon as next year, according to a new report from Bloomberg’s Mark Gurman.
Similar to Google Maps and other mapping apps, Apple’s plan is to allow restaurants and other businesses with…
As the Australian stock market experiences a modest upswing amid geopolitical developments and commodity fluctuations, investors are keenly observing opportunities that may arise from undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be particularly appealing, as they present potential for growth when market conditions stabilize.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Vault Minerals (ASX:VAU) |
A$0.715 |
A$1.17 |
38.6% |
|
Superloop (ASX:SLC) |
A$3.20 |
A$5.66 |
43.5% |
|
Resimac Group (ASX:RMC) |
A$1.12 |
A$2.17 |
48.3% |
|
NRW Holdings (ASX:NWH) |
A$4.81 |
A$9.13 |
47.3% |
|
Liontown Resources (ASX:LTR) |
A$1.22 |
A$2.12 |
42.4% |
|
James Hardie Industries (ASX:JHX) |
A$34.13 |
A$61.30 |
44.3% |
|
Credit Clear (ASX:CCR) |
A$0.285 |
A$0.47 |
39.2% |
|
CleanSpace Holdings (ASX:CSX) |
A$0.70 |
A$1.38 |
49.3% |
|
Betmakers Technology Group (ASX:BET) |
A$0.195 |
A$0.32 |
38.7% |
|
Airtasker (ASX:ART) |
A$0.37 |
A$0.71 |
48.1% |
Click here to see the full list of 32 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.
Here we highlight a subset of our preferred stocks from the screener.
Overview: Eagers Automotive Limited owns and operates motor vehicle dealerships in Australia and New Zealand, with a market cap of A$7.97 billion.
Operations: The company generates revenue primarily from car retailing, amounting to A$12.23 billion, with an additional contribution of A$54.69 million from property.
Estimated Discount To Fair Value: 14.0%
Eagers Automotive is trading at A$30.57, below its fair value estimate of A$35.54, indicating potential undervaluation based on cash flows. Despite a recent strategic partnership with Mitsubishi and a follow-on equity offering raising A$501 million, interest payments are not well covered by earnings. However, earnings are forecast to grow significantly at 21.6% annually over the next three years, surpassing the Australian market’s growth rate of 14.3%.
Overview: NRW Holdings Limited offers diversified contract services to the resources and infrastructure sectors in Australia, with a market cap of A$2.21 billion.
Operations: The company’s revenue is derived from three main segments: Mining at A$1.54 billion, MET at A$932.02 million, and Civil at A$823.72 million.
Estimated Discount To Fair Value: 47.3%
NRW Holdings is trading at A$4.81, significantly below its estimated fair value of A$9.13, suggesting undervaluation based on cash flows. Despite a decline in net income to A$27.67 million for FY2025 and insider selling, earnings are projected to grow substantially at 30.6% annually over the next three years, outpacing the Australian market’s growth rate of 14.3%. However, the dividend yield of 3.43% is not adequately covered by earnings.
President of Xbox game content and studios, Matt Booty, has claimed the company’s competition no longer lies with other game studios and console developers, but “everything else”.
In an interview with The New York Times, primarily…
ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1…
After four weeks at the top, the Xiaomi 17 Pro Max was finally dethroned as the most popular phone in our database. The Chinese maker won’t be too sad about it, though, as it’s replaced at the top by the newly announced Redmi K90 Pro…
VIENNA, Austria, Oct. 26, 2025 (GLOBE NEWSWIRE) — A new global coalition, the RSV Alliance, has been launched to raise awareness about the risks of respiratory syncytial virus (RSV) infections, with a focus on aging populations and…
In a newly published retrospective cohort study, findings showed that patients with testicular germ cell tumors (TGCTs) frequently exhibited paraneoplastic neurologic syndromes (PNSs) prior to their cancer diagnosis, which were often associated…
Refresh for latest…: Continuing their success with anime fare, Sony/Crunchyroll’s release of Chainsaw Man – The Movie: Reze Arc, has pushed the film across the century mark globally, reaching $108M worldwide this weekend.
From…
Artificial intelligence is poised to become a transformative growth driver for African economies, which will also export its own AI in the coming years, according to the head of a data infrastructure company.
At Fortune’s Global Forum in Riyadh, Saudi Arabia, on Sunday, Amini founder and CEO Kate Kallot said her company is building computing power that will enable purpose-built AI solutions for Africa.
The former Nvidia executive also predicted that AI will add $2.9 trillion to Africa’s economy over the next five years as governments begin to view data and computing capacity as critical infrastructure, alongside roads and hospitals. Kallot served as head of emerging areas at Nvidia before departing in 2022 to start Amini.
As infrastructure investments grow, governments are demanding that large language models deployed in Africa actually reflect local realities, given that nearly a billion Africans are still offline while LLMs are trained on internet data, Kallot said.
This new mindset of strategic partnerships has expanded from the governmental level to the private sector, and startups have emerged that will help shape the future of their countries and their economies, she said.
“We’re seeing technology and AI as potentially one of the biggest equalizers that Africa has ever seen,” Kallot added.
But that’s not yet reflected in the global narrative, which doesn’t recognize AI innovation in Africa, she pointed out.
The reality is that the continent is actually a leader in developing AI that’s efficient, responsible, and inclusive—and the rest of the world is about to find out.
“Within the next five to 10 years, we’re going to see African intelligence being exported in other countries across the Global South,” Kallot said.
The negative narrative about Africa is costly, according to Ndidi Okonkwo Nwuneli, CEO of the global advocacy group One Campaign.
That bias has made borrowing costs for African countries more expensive, with negative reporting about the region costing an estimated $4.2 billion. But in fact, certain sectors are seeing returns as high as 10x.
“We’re changing the narrative, and we’re saying Africa is a return on investment, not a risk,” she told Fortune’s Diane Brady. “And this is the time to partner with us with fair financing that delivers results and delivers jobs.”
Flipping the script is also top of mind for Boris Kodjoe, cofounder of the investment and impact platform Full Circle Africa.
The former model and Hollywood actor noted that Africa’s diaspora—the world’s third-largest after China’s and India’s—has been structuring its capital in recent years and is key to the growth story.
Today, Africa’s economy is young, creative, digital, and moving fast, defining itself with culture and technology rather than just its natural resources, Kodjoe explained.
“Africa is the only region where population is getting younger, more connected, and more entrepreneurial all at the same time,” he added. “I think the world is no longer asking ‘why Africa,’ but ‘when can we get in?’ And i think the time is now.”
CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts
Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppository Applicator Demonstrates Statistically Significant Rates of Clinical Remission in Patients with UC in CESSA Phase 3 Trial
Additional Findings Reinforce Rapid and Sustained Drug Release of ngHCA
AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ — Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is presenting three posters highlighting pivotal new data in ulcerative colitis (UC) of the rectum research at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona.
“We are excited to present Cristcot’s data at ACG 2025, which showcases our meaningful contributions across the spectrum of UC research and reinforces the transformative potential of our ngHCA suppository – the first investigational agent to show rapid clinical remission in UC,” said Jennifer J. Davagian, Founder and Chief Executive Officer, Cristcot. “As we progress towards FDA submission and commercialization of our novel therapy, we are focused on close collaboration with the gastroenterology community through forums like ACG to ensure we are best positioned to address the needs of patients, providers, and payers in this field. We look forward to continuing to advance our innovative, patient-centric solutions.”
ACG Presidential Poster Distinction Recognizes Excellence in Clinical Research
The CESSA abstract was selected as an ACG 2025 Presidential Poster Recipient among nearly 6,000 abstracts. The distinction is reserved for approximately five percent of submissions and recognizes high-quality, novel, and clinically meaningful research contributing to advances in gastroenterology.
Pivotal Phase 3 CESSA Trial
Poster Title: Efficacy and Safety of a Novel Investigational Hydrocortisone Acetate Suppository Formulation and Optimized Applicator for Treatment of Active Ulcerative Colitis: Results of the Phase 3 CESSA Trial
Key Findings: The Phase 3 CESSA trial evaluated efficacy and safety of Cristcot’s ngHCA 90 mg suppository administered with the proprietary Sephure® suppository applicator in adults with confirmed active moderate to severe UC.
Efficacy
Safety and Compliance
Additional details on the CESSA trial can be found in Cristcot’s January 2025 press release, available on the News page of its website.
“There is an urgent need for a fast-acting, localized, and easy-to-administer option to manage patients with active ulcerative colitis,” said Raj Devarajan, MD, Global Medical Advisor, Cristcot, and presenting author. “I’m thrilled to share the pivotal CESSA trial results as a Presidential Poster at ACG, which marks a meaningful advancement in this area. The efficacy demonstrated in CESSA, notably clinical responses within two weeks and endoscopic remission by four weeks, has never been achieved in the moderate to severe UC population. Combined with a favorable tolerability profile, these data support this novel HCA combination product to treat UC exacerbations alongside maintenance therapies or as a monotherapy. I look forward to its continued evaluation as a new option for the many patients who continue to face gaps in effective management of this disease.”
Innovation in Pharmacokinetics
Title: Pharmacokinetics and Relative Bioavailability of an Investigational Hydrocortisone Acetate Suppository Administered with a Novel FDA-Cleared Applicator Versus Hydrocortisone Liquid Enema
Key Findings: In this Phase 1 study, the ngHCA suppository administered using the Sephure® suppository applicator demonstrated sustained release with optimal bioavailability that is expected to provide consistent efficacy over the intended treatment period.
New Data Highlights: Clinical Trial Methodology
Title: Recent Recall as an Alternative to Daily Study Participant Diaries in Ulcerative Colitis Trials: Evidence from a Phase 3 Clinical Trial
Key Findings: This prespecified exploratory analysis from the Phase 3 CESSA trial demonstrated that participant-reported UC symptom data collected through recent (3-day) recall correlated with data collected through daily participant diaries. These findings indicate that recent recall offers a reliable, lower-burden alternative to daily diaries for collecting patient-reported outcomes in future UC trials.
Cristcot’s presence at ACG 2025 underscores its commitment to advancing evidence-based, patient-focused solutions that address persistent gaps in ulcerative colitis care.
Additional information, including abstracts, can be found on the ACG 2025 Annual Meeting website.
About Cristcot’s HCA 90 mg Suppository
Cristcot’s investigational hydrocortisone acetate (HCA) 90 mg suppository formulation is a novel corticosteroid therapy delivering a small volume suppository using the Sephure® applicator to ensure precise placement, minimizing discomfort and leakage. Rectally administered topical treatments, including topical corticosteroids, are important treatment options (either alone or in combination with other therapies), for directing delivery to inflammation sites and limiting systemic drug exposure, though there is no FDA-approved corticosteroid suppository on the market. Unlike traditional corticosteroid treatments, Cristcot’s advanced HCA formulation allows for rapid, sustained release with optimal bioavailability, consistent and localized efficacy, and very limited systemic exposure. The innovative delivery system may enhance patient compliance.
About Ulcerative Colitis
UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms often include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients’ quality of life. UC flares frequently originate in the rectum, and untreated inflammation can progress to more extensive disease, leading to hospitalization or surgery. There is no cure for UC and, breakthrough flares, even while taking maintenance medication, is a known characteristic of the disease profile. Over 55% of UC patients experience 3-5 flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential. Gaps remain in addressing flares quickly and effectively, highlighting the need for targeted therapies that can provide rapid symptom relief and remission.
About Cristcot
Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company’s lead asset, a novel hydrocortisone acetate suppository, is positioned to become an important therapeutic option for ulcerative colitis. Cristcot’s diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Austin, Texas.
For more information, please visit www.cristcot.com and connect with us on LinkedIn.
Forward-Looking Statements
Certain information set forth in this press release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Examples of forward-looking statements include, but are not limited to, statements regarding the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company’s products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company’s products; (vi) execution of the Company’s vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws.
These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contacts
Jenny Gizzi, Chief Administrative Officer
Cristcot
[email protected]
Tanner Kaufman / Katie Harris
FTI Consulting
[email protected] / [email protected]
SOURCE Cristcot
